Drug discovery is a long and complex process that requires significant time and resources. The pharmaceutical industry has historically depended on an expensive trial-and-error process that tests large numbers of compounds in the lab to identify potential drug candidates. The process is expensive, costing $2.6 billion per approved drug, and time consuming, taking 10-15 years to bring a new drug to the market. The full pipeline has very low yield, with tens of thousands (or even millions or billions) of compounds tested to produce a single clinical candidate, and a 90% failure rate between entering the clinic and reaching patients.

Modern high throughput assays enable very large numbers of compounds to be tested at early stages of discovery, but the number of viable compounds drops rapidly as a project proceeds through the stages of the drug discovery pipeline.

Each stage of the drug discovery pipeline brings both significant expenses and risks. Very few compounds reach the end of the pipeline and help patients. NME here means “novel molecular entity.” Adapted from source

AI techniques hold out the promise of leveraging data to transform trial-and-error into guided data-driven design. By leveraging powerful machine learning models in combination with rich biological, chemical and physical priors, it ought to be possible to lower failure rates and accelerate timelines for new therapeutics. However, AI techniques remain difficult to develop and deploy. Building large machine learning models requires sophisticated algorithmic understanding, robust cloud infrastructure, and extensive engineering know-how. While the first wave of AI-driven biotech companies has built internal AI infrastructure for discovery campaigns (at high cost), their tools remain internal and specialized to particular biological or chemical systems. As a result, most biotech teams today still lack the ability to deploy and utilize effective AI infrastructure for drug discovery.

Chiron, our new AI powered drug discovery platform, aims to close this gap and enable world-class scientific teams to use state-of-art AI systems. Built upon years of our academic and open-source research, Chiron allows scientists to deploy powerful AI tools without having to write a single line of code.

Chiron uses AI and scientific machine learning algorithms to accelerate the drug discovery process. More specifically, Chiron analyzes biological and chemical datasets in order to build machine learned models that can identify small molecule hits and optimize small molecule leads. Chiron leverages pre-trained chemical foundation models in order to lower data requirements for practical drug discovery. Chiron can help predict the efficacy of potential compounds, identify potential side effects, and prioritize compounds to test in secondary assays.

Chiron can be used today to perform a broad range of scientific machine learning workflows to accelerate the drug discovery process. In particular, Chiron can be used to

Early uses of AI in drug discovery have often been limited by low data availability. Chiron leverages pre-trained foundation models to help systematically lower data requirements so biotech teams can start to leverage AI earlier in their design process.

Our research team is working to expand Chiron’s applicability to every step of the drug discovery and design process. We believe that integrating Chiron into your drug discovery pipeline can reduce your time to IND by months or more.

Chiron is built around a powerful scientific machine learning engine that enables our users to run sophisticated scientific calculations without having to write any new code. Chiron features proprietary datasets and models that users can license to bootstrap their AI efforts before building in-house datasets. Chiron has out-of-box workflows to

Chiron’s scientific machine learning engine is built around a powerful cloud infrastructure that allows users to run sophisticated workflows without having to write any code. Chiron’s no-code capabilities empower scientists to leverage their own biological and chemical expertise without having to go through an intermediary data science team. We believe that providing scientists easy access to powerful AI workflows will unlock creativity and catalyze breakthrough discoveries.

Chiron is built around the DeepChem ecosystem, an open source framework for molecular drug discovery and scientific machine learning. DeepChem was created by our CEO, Dr. Bharath Ramsundar, during the course of his PhD at Stanford. DeepChem offers a wide range of tools and models for scientific machine learning and deep learning, enabling researchers to predict properties, perform virtual screening, and conduct molecular featurization. DeepChem has been cited thousands of times and is used broadly in the academic and industrial drug discovery ecosystems (see this non-exhaustive listing of DeepChem-powered science). The accompanying book, Deep Learning for the Life Sciences, authored by Dr. Ramsundar and colleagues, has become a standard computational reference for the drug discovery community.

Like DataBricks, which is built around the Spark open source ecosystem created by academic research at UC Berkeley, Deep Forest Sciences is built around the DeepChem ecosystem. Chiron productionizes and extends the DeepChem stack to handle real-world drug discovery. Chiron leverages its cloud infrastructure to train models and gather datasets at an industrial scale not feasible with vanilla DeepChem

In particular, Deep Forest Sciences has taken a bet on the power of large scientific foundation models. The DeepChem team, led by Dr. Ramsundar, has developed the ChemBERTa and ChemBERTa-2 models, which helped demonstrate the power of chemical self-supervision to learn meaningful representations of drug-like molecules. By harnessing chemical foundation models such as ChemBERTa, Chiron can leverage vast unlabeled datasets of chemical structures to unlock AI methods in real-world drug discovery even with limited data. Deep Forest Sciences has built both in-house cloud infrastructure and a network of collaborations with leading scientific institutions in order to train and deploy large foundation models for drug discovery and other applications.

Deep Forest Sciences has built a track record of successful partnerships with pharmaceutical companies and academic institutions to apply AI tools to real-world problems. For example, we recently partnered with Third Rock Ventures to accelerate AI-driven drug discovery for their portfolio companies using Chiron, and have several additional partnerships in the works. These projects have validated Chiron on real-world drug discovery campaigns.

Chiron, our AI-powered scientific discovery platform, accelerates drug discovery in order to bring new treatments to patients faster. By equipping world-class biologists and chemists with world-class AI tools, Chiron can unlock breakthrough scientific insights by enabling scientists to marry their intuition to cutting-edge AI workflows. Partnered with Deep Forest Sciences’ team of experts, Chiron will provide your scientists the tools they need to drug challenging targets and design breakthrough therapeutics that will help save lives.

AI methods have already unlocked major scientific advances but have yet to revolutionize drug discovery. Chiron will cross this chasm and transform how scientists discover new medicine by enabling AI-driven drug design.

Email us at partnerships@deepforestsci.com

Blog Posts